Comparative Pharmacology
Head-to-head clinical analysis: PEPCID RPD versus ZANTAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID RPD versus ZANTAC.
PEPCID RPD vs ZANTAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors in gastric parietal cells, inhibiting gastric acid secretion (basal and stimulated).
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
20 mg orally 1-2 times daily for GERD; 40 mg orally once daily for duodenal ulcer or erosive esophagitis. Max 40 mg/day.
150 mg orally twice daily or 50 mg intravenously every 6-8 hours. Alternatively, 300 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life 2.5-3.5 hours (prolonged to ~12-20 hours in renal impairment; CrCl <10 mL/min).
2.5-3 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 20 hours in severe renal impairment (CrCl < 30 mL/min).
Renal (25-30% as unchanged drug); biliary/fecal (approximately 70% as metabolites); hepatic metabolism to famotidine S-oxide.
Renal: 30% unchanged (tubular secretion); hepatic metabolism to N-oxide, S-oxide, and desmethyl ranitidine; biliary/fecal: minimal.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist